Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Corewell Health

Neither a doctor nor a teaching hospital

Research payments

$1,403,796

556 payments

Through program year 2025, Corewell Health is reported as receiving $1,403,796 in research payments, across 556 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $763,362 249
2024 Research $513,184 279
2023 Research $127,251 28

Breakdown

Who paid Research payments · program years 2023–2025
  1. Roche TCRC, Inc. $309,184 29 payments
  2. Pfizer Inc. $173,604 44 payments
  3. Boston Scientific Corporation $139,648 41 payments
  4. United Therapeutics Corporation $121,042 46 payments
  5. Eli Lilly and Company $98,878 3 payments
  6. Indivior Inc. $94,808 208 payments
  7. E.R. Squibb & Sons, L.L.C. $82,569 3 payments
  8. Y-mAbs Therapeutics, Inc. $81,169 34 payments
  9. Genentech, Inc. $48,968 17 payments
  10. Jazz Pharmaceuticals Inc. $37,646 51 payments
Studies the money was for Research payments · program years 2023–2025
  1. Phase II Study in Early Stage Parkinson S Disease Patients $309,184 29 payments
  2. Phase 3 Multicenter Openlabel Study to Assess the Longterm Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine With Or Without Aura in Children and Adolescents 6 to 18 Years of Age $119,380 26 payments
  3. A Phase IV Longitudinal Study of SUBLOCADE (SUBUTEX Prolonged Release) Clinical Outcomes in Adults With Opioid Use Disorder (Opioid Dependence) $94,808 208 payments
  4. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to Pah Standard of Care Or Pah-Specific Background Oral Therapy in Subjects With Who Group I Pulmonary Hypertension $83,990 29 payments
  5. Avant Guard $79,451 14 payments
  6. A Phase 1B Dose Escalation Study of Abemaciclib in Combination With Temozolomide and Irinotecan (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors $76,183 1 payment
  7. Phase 1 Trial With Gd2-Sada:177Lu-Dota Drug Complex in Patients With Recurrent Or Refractory Metastatic Solid Tumors Known to Express Gd2, Including Small Cell Lung Cancer, Sarcoma and Malignant Melanoma $51,819 24 payments
  8. Phase 3 Multicenter Randomized Doubleblind Group Sequential Placebocontrolled Study to Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine With Or Without Aura in Children and Adolescents 6 to 18 Years of Age $50,224 17 payments
  9. A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM) (DISCOVER-HCM) $44,888 1 payment
  10. Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed, ?Refractory Ewing Sarcoma $36,935 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record